Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.
How to Help Protect Your Baby From Rotavirus

Helping to Protect Your Baby by Using RotaTeq
An important reason to vaccinate is to help protect your baby against a severe case of rotavirus.


In a large clinical trial, RotaTeq demonstrated 98% efficacy against severe rotavirus gastroenteritis (RGE) and 74% efficacy against RGE of any severity through the first rotavirus season after vaccination. Also, infants who were vaccinated with RotaTeq were 94% less likely to visit an emergency room and 96% less likely to be hospitalized through the first 2 years after the third dose, due to the types of rotavirus targeted by the vaccine.
» Download the educational brochure
[PDF: 744KB, 2 pages]
 
Important Safety Information
The most common side effects reported were diarrhea, vomiting, fever, runny nose, sore throat, wheezing or coughing, and ear infection. Ask your doctor or health care professional for a more complete list of side effects. Call your child's doctor right away if your child has vomiting, diarrhea, severe stomach pain, blood in their stool or change in their bowel movements, as these may be signs of a serious and life-threatening condition known as intussusception. It is important to contact your health care professional if your child has any of these symptoms at any time after vaccination. RotaTeq should not be given to infants who are allergic to any part of the vaccine.
Who Should Be Vaccinated
Your health care professional can give the first dose of RotaTeq to your baby starting as early as 6 weeks of age.
How RotaTeq Is Given
RotaTeq is not a shot; it is given by mouth. Your child will receive 3 doses of the vaccine. The first dose is given when your child is 6 to 12 weeks of age, the second dose is given 4 to 10 weeks later and the third dose is given 4 to 10 weeks after the second dose. The last (third) dose should be given to your child by 32 weeks of age.
RotaTeq—Extensively Tested
RotaTeq was extensively tested in a large study and was approved by the Food and Drug Administration (FDA) in February 2006.
E-mail this siteE-mail this site
This site is intended only for residents of the United States, its territories, and Puerto Rico.
RotaTeq is a registered trademark of Merck & Co., Inc.
20750349(1)-11/07-RTQ